Google Ads and SEO for medical weight loss practices. High-intent patient acquisition for semaglutide, Ozempic, and medically supervised weight loss programs.
Get My Free AI Marketing AuditPROVEN RESULTS
Every case study below is a real account we ran. No projections, no estimates — just what happened.
238 Conversions at $9.64 CPA
New cosmetic practice, 24.7% conversion rate.
Read full case study →30 Chat Leads in 60 Days
40% convert to new patients — men's health practice.
Read full case study →241% CPA Reduction — $290 to $68
$290 to $68 CPA in 6 months with national campaign expansion.
Read full case study →429 Conversions at $2.35 CPA
Body contouring and aesthetics, 36.9% conversion rate.
Read full case study →Medical weight loss has been transformed by GLP-1 medications like semaglutide. Practices offering medically supervised weight loss programs — particularly those prescribing Wegovy, Ozempic, and compounded semaglutide — are experiencing unprecedented patient demand. The challenge is converting that demand into booked consultations through digital marketing that complies with Google's pharmaceutical advertising policies.
Google Ads for medical weight loss requires careful navigation of prescription drug advertising policies. Campaigns must focus on the medical supervision and program outcomes rather than the medications directly. We build compliant campaign structures that capture the high search volume around GLP-1 weight loss while staying within Google's healthcare advertising guidelines.
The medical weight loss patient has high lifetime value and strong social referral behavior. Patients who achieve significant results with medically supervised programs actively refer friends and family. Building the digital infrastructure to acquire the first patient — and then systematically requesting reviews and referrals — compounds the ROI of every marketing dollar invested.
Procedure-specific campaigns that capture high-intent patients at the exact moment they are searching for your services.
Procedure and location pages that rank for the searches your patients use. Built to compound over time.
Google Maps local pack dominance. Review acquisition. The visibility that drives walk-in and call-in patients.
Medical weight loss is experiencing the most significant patient demand surge of any healthcare category. GLP-1 receptor agonists (semaglutide, tirzepatide) have generated extraordinary mainstream awareness through celebrity disclosure, news coverage, and social media. The result is a patient population that is motivated, informed about medications, and actively seeking providers — but also overwhelmed by options ranging from telehealth startups to medispas to primary care physicians.
The competitive landscape is intensely crowded at the top of the funnel. National telehealth platforms (Hims, Hers, Ro, Calibrate, Found) are spending millions on awareness advertising and have captured significant search real estate. Local practices compete by offering what telehealth cannot: in-person assessment, ongoing physician relationship, integrated lab monitoring, and combined approaches (medication + nutrition + behavioral support) that produce better long-term outcomes.
Patient segmentation matters more in weight loss than in most aesthetic medicine categories. Patients seeking GLP-1 medications specifically ('semaglutide near me,' 'Ozempic for weight loss doctor') are typically further along in their research and closer to conversion. Patients seeking general medical weight loss programs are earlier in consideration. Patients seeking surgical consultation (bariatric surgery) represent a separate, distinct category requiring different content and campaigns. Mixing these in a single undifferentiated approach reduces efficiency significantly.
The regulatory environment for weight loss marketing requires careful navigation. GLP-1 medication marketing has specific FDA considerations, particularly around compounded formulations and off-label promotion. Practices marketing semaglutide compounded preparations must ensure their content accurately reflects the regulatory status of compounded medications. Compliance-aware marketing is not optional — enforcement activity in this category has increased substantially.